Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery

NCT00102037 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00102037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00102037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety of Activated Recombinant FVII as an Add-On Therapy in Spinal Surgery
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2004
Completion date
February 28, 2006
Enrollment
50 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

acquired bleeding disorder, spinal fusion